Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: schadenfreude who wrote (265)	11/23/1998 3:53:00 PM
From: scaram(o)uche	Respond to of 1073

Otaku: Guy's a clown (in positive sense of the word). Loved his presentation, but it was sort of overview stuff that only a veteran pharmachemist would be able to take a critical shot at. He described the EXTRA system, but he didn't attempt to describe a mechanism for the shielding. I was therefore lost. He did, however, take a huge shot at Ligand and Seragen..... indicating that Nipent would be approved soon for CTCL, and that their data was a low-tox (difficult for me to believe with an adenosine deaminase inhibitor) embarrassment to SRGN's data. One other point relevant to biotechs..... we should compare RFS 2000 to IDPH's topo inhibitor. Rick